secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-040929
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic reports Q2 2023 net loss of $15.0M; Phase 3 PKU trial initiated
------------------------------------------------------------------------

- Net loss $15.0M ($0.21/sh) vs $15.8M ($0.22/sh) in Q2 2022; cash $46.3M.
- Revenue $35K from Roche collaboration, down from $152K year-over-year.
- R&D expenses $11.8M; G&A $3.9M, both slightly lower than prior year.
- Initiated pivotal Phase 3 Synpheny-3 trial for labafenogene marselecobac (SYNB1934) in PKU (n=150).
- FDA granted Fast Track designation; WHO approved INN 'labafenogene marselecobac'.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000095017023040929/0000950170-23-040929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000095017023040929/sybx-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer